The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Workshop 6 – Developing a Lean Management culture
Affiliation
Regulatory Affairs and Manufacturing, Amgros I/S
Country
Denmark
1. Current Status, Position
Senior Specialist (oncology pharmacy).
2. Education
- 1993-1995; 1996-2000: Master of Science (pharmacy), University of Copenhagen;
- 1995: Medical Doctor studies, University of Copenhagen;
- 2005: Certified Clinical Pharmacist, Queens University, Belfast;
- 2010: Certified Lean Agent, Capital Region, Denmark;
- 2000-2001: Novo Nordisk, Regulatory Affairs, Copenhagen;
- 2001-2005: Hospital pharmacist, State University Hospital, Copenhagen;
- 2005-2013: Production Manager at the Cytotoxic Compounding Unit at the University Hospital Herlev, Copenhagen within the Capital Region Hospital Pharmacy;
- 2013 – present : Senior specialist within oncology pharmacy on behalf of all the Danish hospital pharmacies at Amgros.
3. Research Area
During his employment at the Capital Regions Hospital Pharmacy he´s got a general knowledge about the various areas of a production setup regarding compounding of cytotoxics including Good Manufacturing Practice, production planning, management of staff, dose banding, drug dossiers incl. stability data, occupational issues incl. contamination etc. It was in that setting he got his experience with lean and lean management over 5 years.
“The Stability of Pharmaceuticals” is a research area within Amgros. Many pharmaceuticals are produced or have their preparation completed at the hospital pharmacies. Therefore, it is necessary for the hospital pharmacies to be knowledgeable about the medicine’s shelf-life after the process that takes place at the hospital pharmacies. His job is to gather information about the stability of cytotoxic drugs used at the oncology and haematology wards at the hospitals in Denmark.
Conflict of interest: None